Home/Pipeline/VTX2735

VTX2735

Recurrent Pericarditis

Phase 2In Development

Key Facts

Indication

Recurrent Pericarditis

Phase

Phase 2

Status

In Development

Company

Ventyx Biosciences

About Ventyx Biosciences

Ventyx Biosciences leverages expertise in medicinal chemistry, structural biology, and immunology to discover and develop differentiated oral therapeutics for diseases with high unmet need. Its clinical-stage pipeline is built around two core platforms: NLRP3 inflammasome inhibitors (with both peripheral and CNS-penetrant candidates) and immunomodulators for inflammatory bowel disease (S1P1R and TYK2). The company's strategic acquisition by Lilly in early 2026 validates its platform and provides significant resources to advance its programs.

View full company profile

Therapeutic Areas

Autoimmune Diseases Inflammatory Diseases Neurodegenerative Diseases Cardiometabolic Diseases

Other Recurrent Pericarditis Drugs

Drug	Company	Phase	Status
ARCALYST (rilonacept)	Kiniksa Pharmaceuticals	Commercial	Approved and Marketed
KPL-387	Kiniksa Pharmaceuticals	Phase 2/3	Active, Recruiting (Study KPL-387-C211)